+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Skin Cancer Drugs Global Market Report 2024

  • PDF Icon

    Report

  • 175 Pages
  • February 2024
  • Region: Global
  • The Business Research Company
  • ID: 5734942
The skin cancer drugs market size has grown rapidly in recent years. It will grow from $4.16 billion in 2023 to $4.73 billion in 2024 at a compound annual growth rate (CAGR) of 13.8%. The growth observed in the historical period can be ascribed to factors such as the rising occurrence of skin cancer, concerns related to sun exposure and UV radiation, advancements in diagnostic methods, shifting demographics with an aging population, as well as regulatory approvals and ongoing clinical research.

The skin cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $7.65 billion in 2028 at a compound annual growth rate (CAGR) of 12.8%. The anticipated growth in the forecast period can be credited to advancements in immunotherapy, ongoing research in precision medicine and biomarkers, implementation of patient education and awareness programs, global collaborations in research initiatives, and the expansion of therapeutic options. Major trends expected in the forecast period encompass the utilization of combination therapies for heightened effectiveness, the adoption of personalized medicine approaches, the creation of topical treatments, a heightened focus on early detection and prevention, and the exploration of novel drug delivery systems.

The significant increase in skin cancer prevalence is fueling the demand for drugs to address this condition. To cater to the growing cases of skin cancer, there is a continuous development of innovative drugs. In 2022, The American Cancer Society reported that around 99,780 new cases of melanoma skin cancer were diagnosed, with an estimated 7,650 deaths annually. This surge in skin cancer cases is contributing to an elevated demand for skin cancer drugs, consequently propelling the market.

The rise in sun exposure and tanning among individuals is anticipated to drive the future growth of the skin cancer drug market. Sun exposure, representing the time spent in sunlight with potential positive and negative effects on the skin and overall health, coupled with tanning resulting from prolonged exposure to sunlight or other sources of ultraviolet (UV) radiation, contributes to skin diseases such as skin cancer. With advancements in treatment options and increased awareness, there is a notable expansion in the skin cancer drugs market. For example, a survey by the American Academy of Dermatology in April 2022 revealed that 63% of 1000 surveyed US adults reported getting a tan in 2021, marking a 9% increase from the previous year's 54%. Moreover, one-third of respondents (33%) experienced sunburn, showing an eight-point rise compared to the previous year's 25%. Thus, the heightened sun exposure and tanning practices among individuals are steering the growth of the skin cancer drug market.

The growing utilization of biologics and targeted therapies poses a challenge in the skin cancer drugs market. Targeted therapies specifically aim at melanoma cells, contrasting with chemical drugs that affect any rapidly dividing cells. Given their precision in targeting only melanoma-causing cells, targeted therapies are preferred by physicians for skin cancer treatment. This preference is anticipated to impact the sales of traditional chemical skin cancer drugs, thereby restricting the potential growth of the skin cancer drugs market.

Companies operating in the Skin Cancer Market are increasingly opting for Strategic Alliances with other market players. Such alliances are seen as beneficial in enhancing R&D capabilities, expediting new drug development, and strengthening competitive positions. For instance, Leo Pharma strategically aligned with PellePharm to jointly develop a drug for treating Gorlin syndrome, a rare form of skin cancer. MorphoSys collaborated with LEO Pharma to develop antibodies for skin cancer treatment. Pfizer entered a strategic alliance with Merck KGaA to produce an innovative drug for skin cancer.

Major companies in the skin cancer drugs market are placing emphasis on securing product approvals to better cater to existing demand. The increase in product approvals results from a combination of scientific advancements, regulatory adjustments, market demands, and patient advocacy. For example, in March 2023, Incyte Corporation, a US-based pharmaceutical company specializing in skin cancer drugs, announced FDA approval for Zynyz (Retifanlimab-Dlwr) in the treatment of metastatic or recurrent Merkel cell carcinoma (MCC). Zynyz, a monoclonal antibody targeting programmed death receptor-1 (PD-1), obtained expedited FDA approval based on tumor response rate and duration of response (DOR). Its continued clearance for this use is contingent upon confirmation of therapeutic benefits in confirmatory studies.

In April 2022, Regeneron, a US-based biotechnology company, acquired Checkmate Pharmaceuticals for $250 million. This acquisition expands Regeneron's immuno-oncology research efforts, focusing on potential approaches for challenging-to-treat cancers, particularly in the domain of skin cancer drugs. Checkmate Pharmaceuticals, a US-based company in the skin cancer drugs sector, aligns with Regeneron's strategic objectives.

Major companies operating in the skin cancer drugs market report are Pfizer Inc., Meda Pharmaceuticals, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Mylan N.V., Daiichi Sankyo Company Limited, Bausch Health Companies Inc., Valeant Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Varian Medical Systems Inc., Kyowa Kirin Co. Ltd., QIAGEN N.V., Elekta AB, Cannabis Science Inc., LEO Pharma A/S, Aqua Pharmaceuticals, iCAD Inc., AB Science, Cellceutix Corporation, Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Seattle Genetics Inc. North America was the largest region in the skin cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the global skin cancer drugs market during the forecast period. The regions covered in the skin cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The primary classifications of skin cancer drugs include actinic keratoses (AK), basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. Actinic keratoses manifest as broad, rough skin patches that may transform into cancerous growths, typically emerging on sun-exposed areas such as the face, scalp, hands, and chest, with a higher incidence in fair-skinned individuals. Terms such as solar keratosis and senile keratosis are used interchangeably to describe this condition. The various drug classes employed in skin cancer treatment encompass chemotherapy, immunotherapy, targeted agents, and other drugs, with applications extending to hospitals, cancer research centers, and clinics.

The skin cancer drugs market research report is one of a series of new reports that provides skin cancer drugs market statistics, including skin cancer drugs industry global market size, regional shares, competitors with a skin cancer drugs market share, detailed skin cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the skin cancer drugs industry. This skin cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The countries covered in the skin cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The skin cancer drugs market consists of sales of vismodegib (Erivedge) and sonidegib (Odomzo). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary2. Skin Cancer Drugs Market Characteristics3. Skin Cancer Drugs Market Trends and Strategies
4. Skin Cancer Drugs Market - Macro Economic Scenario
4.1. Impact of High Inflation on the Market
4.2. Ukraine-Russia War Impact on the Market
4.3. COVID-19 Impact on the Market
5. Global Skin Cancer Drugs Market Size and Growth
5.1. Global Skin Cancer Drugs Market Drivers and Restraints
5.1.1. Drivers of the Market
5.1.2. Restraints of the Market
5.2. Global Skin Cancer Drugs Historic Market Size and Growth, 2018-2023, Value ($ Billion)
5.3. Global Skin Cancer Drugs Forecast Market Size and Growth, 2023-2028, 2033F, Value ($ Billion)
6. Skin Cancer Drugs Market Segmentation
6.1. Global Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Actinic Keratoses (AK)
  • Basal cell carcinoma (BCC)
  • Squamous cell carcinoma (SCC)
  • Melanoma
6.2. Global Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Chemotherapy
  • Immunotherapy
  • Targeted Agents & Other Drugs
6.3. Global Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Cancer Research Centers
  • Clinics
7. Skin Cancer Drugs Market Regional and Country Analysis
7.1. Global Skin Cancer Drugs Market, Split by Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Skin Cancer Drugs Market, Split by Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Skin Cancer Drugs Market
8.1. Asia-Pacific Skin Cancer Drugs Market Overview
Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Skin Cancer Drugs Market
9.1. China Skin Cancer Drugs Market Overview
9.2. China Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Skin Cancer Drugs Market
10.1. India Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Skin Cancer Drugs Market
11.1. Japan Skin Cancer Drugs Market Overview
11.2. Japan Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Skin Cancer Drugs Market
12.1. Australia Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Skin Cancer Drugs Market
13.1. Indonesia Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Skin Cancer Drugs Market
14.1. South Korea Skin Cancer Drugs Market Overview
14.2. South Korea Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Skin Cancer Drugs Market
15.1. Western Europe Skin Cancer Drugs Market Overview
15.2. Western Europe Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Skin Cancer Drugs Market
16.1. UK Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Skin Cancer Drugs Market
17.1. Germany Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Skin Cancer Drugs Market
18.1. France Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Skin Cancer Drugs Market
19.1. Italy Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Skin Cancer Drugs Market
20.1. Spain Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Skin Cancer Drugs Market
21.1. Eastern Europe Skin Cancer Drugs Market Overview
21.2. Eastern Europe Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Skin Cancer Drugs Market
22.1. Russia Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Skin Cancer Drugs Market
23.1. North America Skin Cancer Drugs Market Overview
23.2. North America Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Skin Cancer Drugs Market
24.1. USA Skin Cancer Drugs Market Overview
24.2. USA Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Skin Cancer Drugs Market
25.1. Canada Skin Cancer Drugs Market Overview
25.2. Canada Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Skin Cancer Drugs Market
26.1. South America Skin Cancer Drugs Market Overview
26.2. South America Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Skin Cancer Drugs Market
27.1. Brazil Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Skin Cancer Drugs Market
28.1. Middle East Skin Cancer Drugs Market Overview
28.2. Middle East Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Skin Cancer Drugs Market
29.1. Africa Skin Cancer Drugs Market Overview
29.2. Africa Skin Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Skin Cancer Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Skin Cancer Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Skin Cancer Drugs Market Competitive Landscape and Company Profiles
30.1. Skin Cancer Drugs Market Competitive Landscape
30.2. Skin Cancer Drugs Market Company Profiles
30.2.1. Pfizer Inc.
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Meda Pharmaceuticals
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. Roche Holding AG
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Merck & Co. Inc.
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. AbbVie Inc.
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Skin Cancer Drugs Market Other Major and Innovative Companies
31.1. Novartis International AG
31.2. Sanofi SA
31.3. Bristol Myers Squibb Company
31.4. AstraZeneca PLC
31.5. GlaxoSmithKline plc
31.6. Takeda Pharmaceutical Company Limited
31.7. Eli Lilly and Company
31.8. Boehringer Ingelheim International GmbH
31.9. Mylan N.V.
31.10. Daiichi Sankyo Company Limited
31.11. Bausch Health Companies Inc.
31.12. Valeant Pharmaceuticals
31.13. Sun Pharmaceutical Industries Ltd
31.14. Ipsen Pharma
31.15. Varian Medical Systems Inc.
32. Global Skin Cancer Drugs Market Competitive Benchmarking33. Global Skin Cancer Drugs Market Competitive Dashboard34. Key Mergers and Acquisitions in the Skin Cancer Drugs Market
35. Skin Cancer Drugs Market Future Outlook and Potential Analysis
35.1 Skin Cancer Drugs Market in 2028 - Countries Offering Most New Opportunities
35.2 Skin Cancer Drugs Market in 2028 - Segments Offering Most New Opportunities
35.3 Skin Cancer Drugs Market in 2028 - Growth Strategies
35.3.1 Market Trend-based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic and Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright and Disclaimer

Executive Summary

Skin Cancer Drugs Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on skin cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
  • Report will be updated with the latest data and delivered to you with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for skin cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
  • The impact of higher inflation in many countries and the resulting spike in interest rates.
  • The continued but declining impact of COVID-19 on supply chains and consumption patterns.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Report Scope

Markets Covered:
1) By Type: Actinic Keratoses (AK); Basal cell carcinoma (BCC); Squamous cell carcinoma (SCC); Melanoma
2) By Drug Class: Chemotherapy; Immunotherapy; Targeted Agents & Other Drugs
3) By End-users: Hospitals; Cancer Research Centers; Clinics

Key Companies Mentioned: Pfizer Inc.; Meda Pharmaceuticals; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes

Delivery Format: PDF, Word and Excel Data Dashboard

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Pfizer Inc.
  • Meda Pharmaceuticals
  • Roche Holding AG
  • Merck & Co. Inc.
  • AbbVie Inc.
  • Novartis International AG
  • Sanofi SA
  • Bristol Myers Squibb Company
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH
  • Mylan N.V.
  • Daiichi Sankyo Company Limited
  • Bausch Health Companies Inc.
  • Valeant Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd
  • Ipsen Pharma
  • Varian Medical Systems Inc.
  • Kyowa Kirin Co. Ltd.
  • QIAGEN N.V.
  • Elekta AB
  • Cannabis Science Inc.
  • LEO Pharma A/S
  • Aqua Pharmaceuticals
  • iCAD Inc.
  • AB Science
  • Cellceutix Corporation
  • Eisai Co. Ltd.
  • Otsuka Pharmaceutical Co. Ltd.
  • Seattle Genetics Inc.

Methodology

Loading
LOADING...

Table Information